Cargando…
Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展
Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell. When binding to the ligand on tumor cells, PD-1 as an immunosuppressive molecule, can inhibit the immune function of...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849032/ https://www.ncbi.nlm.nih.gov/pubmed/33478191 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.49 |
_version_ | 1783645235440517120 |
---|---|
collection | PubMed |
description | Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell. When binding to the ligand on tumor cells, PD-1 as an immunosuppressive molecule, can inhibit the immune function of T cells, thus tumor immune escape. For example, depletion of peripheral effector T cell and accelerate the transformation of effector T cells into regulator T cells. To solve this problem, PD-1 antibody is used to bind to PD-1 on T cells to inhibit the interaction between PD-1 on the T cells and PD-L1 on the tumor cells so that it can restore the function of T cells to kill tumor cell. PD-1 antibodies, such as Nivolumab and Pembrolizumb, are approved as a first-line treatment for advanced non-small cell lung cell cancer. However, due to the interaction of tumor cells, T cells and cytokines, some patients developed drug resistance which reduces the efficacy of immunotherapy. Hence, how to overcome resistance has become a urgent problem. Cereblon (CRBN), a substrate receptor of the DDB1-cullin-RING E3 ubiquitin ligase complex and the only known molecular receptor of immunoregulatory drugs, has been found to reverse PD-1 antibody resistance by binding to CRBN regulatory agents (CMS), exert T cell immune function by regulating proliferation, activation and metabolism of T cell. In this paper, the mechanism of down-regulation of T cells leading to resistance of PD-1 antibody in lung cancer, the mechanism of CRBN regulating T cells, and research progress of CRBN regulator in the treatment of lung cancer were reviewed. |
format | Online Article Text |
id | pubmed-7849032 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-78490322021-02-04 Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 Zhongguo Fei Ai Za Zhi 综述 Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell. When binding to the ligand on tumor cells, PD-1 as an immunosuppressive molecule, can inhibit the immune function of T cells, thus tumor immune escape. For example, depletion of peripheral effector T cell and accelerate the transformation of effector T cells into regulator T cells. To solve this problem, PD-1 antibody is used to bind to PD-1 on T cells to inhibit the interaction between PD-1 on the T cells and PD-L1 on the tumor cells so that it can restore the function of T cells to kill tumor cell. PD-1 antibodies, such as Nivolumab and Pembrolizumb, are approved as a first-line treatment for advanced non-small cell lung cell cancer. However, due to the interaction of tumor cells, T cells and cytokines, some patients developed drug resistance which reduces the efficacy of immunotherapy. Hence, how to overcome resistance has become a urgent problem. Cereblon (CRBN), a substrate receptor of the DDB1-cullin-RING E3 ubiquitin ligase complex and the only known molecular receptor of immunoregulatory drugs, has been found to reverse PD-1 antibody resistance by binding to CRBN regulatory agents (CMS), exert T cell immune function by regulating proliferation, activation and metabolism of T cell. In this paper, the mechanism of down-regulation of T cells leading to resistance of PD-1 antibody in lung cancer, the mechanism of CRBN regulating T cells, and research progress of CRBN regulator in the treatment of lung cancer were reviewed. 中国肺癌杂志编辑部 2021-01-20 /pmc/articles/PMC7849032/ /pubmed/33478191 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.49 Text en 版权所有©《中国肺癌杂志》编辑部2021 This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 |
title | Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 |
title_full | Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 |
title_fullStr | Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 |
title_full_unstemmed | Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 |
title_short | Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展 |
title_sort | cereblon调节t细胞逆转pd-1抗体治疗肺癌耐药的研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849032/ https://www.ncbi.nlm.nih.gov/pubmed/33478191 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.49 |
work_keys_str_mv | AT cereblondiàojiétxìbāonìzhuǎnpd1kàngtǐzhìliáofèiáinàiyàodeyánjiūjìnzhǎn AT cereblondiàojiétxìbāonìzhuǎnpd1kàngtǐzhìliáofèiáinàiyàodeyánjiūjìnzhǎn AT cereblondiàojiétxìbāonìzhuǎnpd1kàngtǐzhìliáofèiáinàiyàodeyánjiūjìnzhǎn |